Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation

European Journal of Clinical Pharmacology

Volumn 69, Issue 8, 2013, Pages 1533-1542

  Guy Viterbo, V ^a   Scohy, A ^a   Verbeeck, R K ^a   Reding, R ^b   Wallemacq, P ^a   Musuamba, Flora Tshinanu ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Liver transplantation; Pediatrics; Population pharmacokinetics; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

TACROLIMUS;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; HEMATOCRIT; HUMAN; INFANT; LIVER TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY ANALYSIS;

ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; TACROLIMUS;

EID: 84880508530     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1501-0     Document Type: Article

References (36)

1. Flanagan WM, Corthésy B, Bram RJ, Crabtree GR (1991) Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 352(6338):803-807
2. Kelly D (2006) Current issues in pediatric transplantation. Pediatr Transplant 10(6):712-720
3. Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43(10):623-653
4. Naesens M, Kuypers D, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4(2):481-508
5. Rodriguez-Peralverez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK (2012) Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant 12:2797-2814
6. D'Antiga L, Dhawan A, Portmann B, Francavilla R, Rela M, Heaton N, Mieli-Vergani G (2002) Late cellular rejection in paediatric liver transplantation: aetiology and outcome. Transplantation 73(1):80-84
7. Staatz CE, Goodman LK, Tett SE (2010) Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 49(3):141-175
8. Willis C, Staatz CE, Tett SE (2003) Bayesian forecasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients. Ther Drug Monit 25(2):158-166
9. Yasuhara M, Hashida T, Toraguchi M et al (1995) Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc 27(1):1108-1110
10. Sam WJ, Aw M, Quak SH, Lim SM, Charles BG, Chan SY, Ho PC (2000) Population pharmacokinetics of tacrolimus in Asian pediatric liver transplant patients. Br J Clin Pharmacol 50(6):531-541
11. Sam WJ, Tham LS, Holmes MJ, Aw M, Quak SH, Lee KH, Lim S et al (2006) Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. Clin Pharmacokinet 45(1):59-75
12. Staatz CE, Taylor PJ, Lynch SV, Willis C, Charles BG, Tett SE (2001) Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation 72(6):1056-1061
13. García Sánchez MJ, Manzanares C, Santos-Buelga D, Blázquez A, Manzanares J, Urruzuno P, Medina E (2001) Covariate effects on the apparent clearance of tacrolimus in pediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet 40(1):63-71
14. Fukudo M, Yano I, Masuda S et al (2006) Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 80(4):331-345
15. Wallin JE, Bergstrand M, Wilczek HE, Nydert PS, Karlsson MO, Staatz CE (2011) Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. Ther Drug Monit 33(6):663-672
16. de Wildt SN, van Schaik RH, Soldin OP et al (2011) The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur J Clin Pharmacol 67(12):1231-1241
17. Antignac M, Hulot JS, Boleslawski E, Hannoun L, Touitou Y, Farinotti R, Lechat P, Urien S (2005) Population pharmacokinetics of tacrolimus in full liver transplant patients: modeling of the post-operative clearance. Eur J Clin Pharmacol 61(5-6):409-416
18. Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE (2003) Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl 9(2):130-137
19. Fukatsu S, Yano I, Igarashi T et al (2001) Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 57(6-7):479-484
20. Zahir H, McLachlan AJ, Nelson A, McCaughan G, Gleeson M, Akhlaghi F (2005) Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit 27(4):422-430
21. Blanchet B, Duvoux C, Costentin CE et al (2008) Pharmacokinetic- pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period. Ther Drug Monit 30(4):412-418
22. Li D, Lu W, Zhu JY, Gao J, Lou YQ, Zhang GL (2007) Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther 32(5):505-515
23. Oteo I, Lukas JC, Leal N, Suarez E, Valdivieso A, Gastaca M, Ortiz de Urbina J, Calvo R (2013) Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. Eur J Clin Pharmacol 69:65-74
24. Wallemacq P, Armstrong VW, Brunet M et al (2009) Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 31(2):139-152
25. Sheiner LB, Beal SL (1983) Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 11(3):303-319
26. Alak AM, Cook M, Bekersky I (1997) Measurement of tacrolimus (FK506) and its metabolites: a review of assay development and application in therapeutic drug monitoring and pharmacokinetic studies. Ther Drug Monit 19(1):338-351
27. Wallemacq P, Goffinet JS, O'Morchoe S et al (2009) Multisite analitical evaluation of the Abbott ARCHITECT tacrolimus assay. Ther Drug Monit 31(2):198-204
28. Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79:241-257
29. Bertrand J, Comets E, Mentre F (2008) Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters. J Biopharm Stat 18(6):1084-1102
30. Hooker AC, Staatz CE, Karlsson MO (2007) Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 24(12):2187-2197
31. Schwartz GJ, Work DF (2009) New equations to estimate GFR in children with CKD. Clin J Am Soc Nephrol 4(11):1832-1843
32. Comets E, Brendel K, Mentré F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the NDPE add-on package for R. Comput Methods Programs Biomed 90(2):154-166
33. Jusko WJ, Piekoszewski W, Klintmalm GB et al (1995) Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 57(3):281-290
34. Zhao W, Elie V, Roussey G et al (2009) Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther 86(6):609-618
35. Zhao W, Fakhoury M, Baudouin V et al (2013) Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. Eur J Clin Pharmacol 69(2):189-195
36. Uesugi M, Masuda S, Katsura T et al (2006) Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 16(2):119-127